Tumor Differentiation is Correlated with Estrogen Receptor Beta (ERβ) Expression but Not with Interleukin-6 (IL-6) Expression in Colorectal Carcinoma
Abstract
BACKGROUND: Colorectal carcinoma (CRC), the third most common malignant disease worldwide, is associated with estrogen receptor β (ERβ) and interleukin-6 (IL-6). ERβ is known to down-regulate IL-6 in prostate cancer, lung carcinoma, and CRC cell lines; however, its effect on human with CRC remains unclear. Therefore, this study was conducted to investigate the association between ERβ and IL-6 expressions with the clinicopathological features of CRC.
METHODS: This was an analytic observational study using 40 paraffin blocks of CRC patients. ERβ and IL-6 expression was measured by immunohistochemistry (IHC) staining. The percentage of immunoreactive tumor cell per 1000 cells was manually recorded and tumor differentiation as well as tumor infiltration were determined. Tumor differentiation was graded according to the World Health Organization (WHO) 2010 criteria, while tumor infiltration was defined based on the American Joint Committee on Cancer (AJCC) 8th edition.
RESULTS: Fifty percent of samples were well-differentiated CRC, and 57.5% samples were T3 infiltration tumors. IHC staining showed 35.5% of samples were positive for ERβ expression, while 70.86% were positive for IL-6 expression. There were negative correlation of ERβ expression with tumor differentiation (p=0.018; r=-0.371), but no correlation with tumor infiltration (p=0.836) were found. There was no correlation between ERβ expression with IL-6 expression (p=0.154).
CONCLUSION: There is statistically significant correlation between tumor differentiation and ERβ expression, wherein improved tumor differentiation is linked to higher levels of positive ERβ expression. However, there is no discernible relationship between IL-6 and tumor differentiation. These findings suggest that while IL-6 was involved in the growth of the tumor, ERβ expression might have an impact on tumor differentiation.
KEYWORDS: colorectal carcinoma, estrogen receptor beta, interleukin-6, cell differentiation
Full Text:
PDFReferences
Kementrian Kesehatan RI. Profil Kesehatan Indonesia 2018. Jakarta: Kementrian Kesehatan RI; 2019, article.
World Health Organization [Internet]. Cancer [cited 2024 Aug 1]. Available from: https://www.who.int/.
American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. Atlanta: American Cancer Society; 2020, article.
Williams C, DiLeo A, Niv Y, Gustafsson JÅ. Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett. 2016; 372(1): 48-56, CrossRef.
Hases L, Indukuri R, Birgersson M, Nguyen-Vu T, Lozano R, Saxena A, et al. Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes. Cancer Lett. 2020; 492: 54-62, CrossRef.
Chen YY, Ma ZB, Xu HY, Shi LJ, Li DY, Sun LY, et al. IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis. Int J Clin Exp Med. 2015; 8(8): 12009-17, PMID.
Zeng J, Tang ZH, Liu S, Guo SS. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017; 23(10): 1780-6, CrossRef.
Skrzycki M. Superoxide dismutase and the sigma1 receptor as key elements of the antioxidant system in human gastrointestinal tract cancers. Open Life Sci. 2021; 16(1): 1225-39, CrossRef.
Retnowarnadi A, Kresno SB, Arif M. Association of obesity and breast cancer risk: The role of estrogen, tumor necrosis factor-alpha, and adiponectin as risk factors (preliminary study). Indones Biomed J. 2009; 1(1): 45-52, CrossRef.
Wulandari F, Hanifa M. Integrative bioinformatics reveals the lactate dehydrogenase B (LDHB) significance in colon adenocarcinoma. Mol Cell Biomed Sci. 2023; 7(2): 98-108, CrossRef.
Kementrian Kesehatan RI. Keputusan Menteri Kesehatan Republik Indonesia No.HK.01.07/Menkes/406/2018 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Kolorektal. Jakarta: Kementrian Kesehatan RI; 2018, article.
Elbanna HG, Ebrahim MA, Abbas AM, Zalata K, Hashim MA. Potential value of estrogen receptor beta expression in colorectal carcinoma: Interaction with apoptotic index. J Gastrointest Cancer. 2012; 43(1): 56-62, CrossRef.
Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 1997; 25(12): 2424-9, CrossRef.
Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer. Int J Oncol. 2014; 44(4): 1032-40, CrossRef.
Roshan MHK, Tambo A, Pace NP. The role of testosterone in colorectal carcinoma: pathomechanisms and open questions. EPMA J. 2016; 7(1): 22. doi:10.1186/s13167-016-0071-5, CrossRef.
Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 2015; 5: 19, CrossRef.
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017, NLMID.
Gunasekaran V, Ekawati NP, Sumadi IWJ. Karakteristik klinikopatologi karsinoma kolorektal di RSUP Sanglah, Bali, Indonesia tahun 2013-2017. Intisari Sains Medis. 2019; 10(3): 552-6, CrossRef.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017; 3(4): 464-71, CrossRef.
Dharwadkar P, Zaki TA, Murphy CC. Colorectal cancer in younger adults. Hematol Oncol Clin North Am. 2022; 36(3): 449-70, CrossRef.
Asgari M, Morakabati A. Estrogen receptor beta expression in prostate adenocarcinoma. Diagn Pathol. 2011; 6(1): 61. doi:10.1186/1746-1596-6-61, CrossRef.
Shafiei M, Mafi A, Nilipour Y, Sourati A, Sasanpour P, Tabatabaeefar M. Estrogen receptor expression in glial tumors of Iranian patients: A single center experience. Iran J Pathol. 2020; 15(1): 8-12, CrossRef.
Uciechowski P, Dempke WCM. Interleukin-6: A masterplayer in the cytokine network. Oncol. 2020; 98(3): 131-7, CrossRef.
Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020; 11: 827. doi: 10.3389/fimmu.2020.00827, CrossRef.
Lin Y, He Z, Ye J, Liu Z, She X, Gao X, et al. Progress in understanding the IL-6 / STAT3 pathway in colorectal cancer. Onco Targets Ther. 2020; 13: 13023-32, CrossRef.
DOI: https://doi.org/10.18585/inabj.v16i5.3324
Copyright (c) 2024 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
